Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
Sex
Ages
Volunteers
Inclusion criteria
Male and female, aged at least 18 years old at the Screening visit.
A clear chest X-ray within 3 months prior to Baseline visit.
A diagnosis of adult-onset RA (of at least six months duration but not longer than 15 years prior to Screening) as defined by the 1987 American College of Rheumatology classification criteria.
Active RA disease at Screening and Baseline as defined by:
Must have received a stable dose of MTX with or without folic acid for at least 3 months prior to Baseline visit. The minimum dose is 10 mg MTX weekly.
Patient must be willing to attend for a Week 52 X-ray of the hands and feet even if they are no longer receiving study treatment but have not withdrawn their informed consent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal